{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006973488,0.0002467896,0.0006357944,0.00003361656,0.0002603738,0.0000720822,0.001251689,0.0002007466,0.00004622863],"category_scores_gemma":[0.0005765868,0.0001608461,0.00004649681,0.00005256501,0.0002060015,0.00001620898,0.0004937221,0.0002162379,0.00002596397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004662613,"about_ca_system_score_gemma":0.0002077226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004543337,"about_ca_topic_score_gemma":0.0004320239,"domain_scores_codex":[0.9981857,0.0003340799,0.0003460566,0.000476838,0.0001503516,0.0005069915],"domain_scores_gemma":[0.9981112,0.0001248706,0.0004152753,0.0011606,0.00008506836,0.0001030144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9413875,0.001788273,0.002504655,0.00001270507,0.000165384,0.00003757251,0.0001018991,0.000006033888,0.03283108,0.0001461193,0.001164539,0.01985425],"study_design_scores_gemma":[0.8913029,0.01335624,0.002974534,0.00001950546,0.00007182873,0.000003948862,0.00003868295,0.00003722726,0.007827321,0.00002135625,0.08407936,0.0002670525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826784,0.0001287684,0.00002180999,0.0005276924,0.0009830422,0.00214652,0.00007460718,0.00001237254,0.01342677],"genre_scores_gemma":[0.9974016,0.0001467308,0.000793519,0.0003195207,0.0006383751,0.0002641666,0.0001961016,0.00003031827,0.0002096896],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08291481,"threshold_uncertainty_score":0.6559113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05756250214883237,"score_gpt":0.3665577832550817,"score_spread":0.3089952811062494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}